The primary active ingredient of cannabis, delta-9-tetrahydrocannabinol, increases random neural activity — termed “neural noise” — in the brains of healthy humans, according to research published in Biological Psychiatry.
"The dose-dependent and strong positive relationship between [THC and psychosis-like effects] suggest[s] that the psychosis-like effects of cannabis may be related to neural noise which disrupts the brain’s normal information processing," said Jose Cortes-Briones, PhD, a postdoctoral associate in psychiatry at Yale School of Medicine.
The researchers studied how THC affected electrical brain activity in 24 participants in a 3-day study during which they received 2 doses of intravenous THC or placebo.
If the link between neural noise and psychosis is confirmed, this could help researchers get closer to understanding the biology behind some of the symptoms of schizophrenia.
"This interesting study suggests a commonality between the effects on the brain of the major active ingredient in marijuana and symptoms of schizophrenia," said John Krystal, MD, editor of Biological Psychiatry. "The impairment of cortical function by [THC] could underlie some of the cognitive effects of marijuana.
"Not only does this finding aid our understanding of the processes underlying psychosis, it underscores an important concern in the debate surrounding medical and legalized access to marijuana."
Several studies have demonstrated that the primary active constituent of cannabis, delta-9-tetrahydrocannabinol induces transient psychosis-like effects in healthy subjects similar to those observed in schizophrenia. However, the mechanisms underlying these effects are not clear.
A new study reports that delta-9-tetrahydrocannabinol increases random neural activity, termed neural noise, in the brains of healthy human subjects. The findings suggest that increased neural noise may play a role in the psychosis-like effects of cannabis.
The investigators studied the effects of delta-9-tetrahydrocannabinolon electrical brain activity in 24 human subjects who participated in a three-day study during which they received two doses of intravenous delta-9-THC or placebo in a double-blind, randomized, cross-over, and counterbalanced design.
Enjoying our content?
Thanks for visiting Psychiatry Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Psychiatry Advisor. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Evidence-Based Guidance
- Conference Coverage
- Unique Psychiatry Case Studies
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.